|
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
RECRUITINGSponsored by Hoffmann-La Roche
Actively Recruiting
SponsorHoffmann-La Roche
Started2026-09-23
Est. completion2029-01-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07827586
Summary
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching from intravenous (i.v.) ocrelizumab to s.c. ocrelizumab, or switching from a prior disease-modifying therapy (DMT) to s.c. ocrelizumab.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Diagnosis of RRMS according to the revised McDonald criteria (2017 or 2024 revisions). * Initiation of ocrelizumab s.c in accordance with routine clinical practice and local prescribing information. * The decision to initiate ocrelizumab s.c. has been made by the treating physician prior to and independently of study participation. * Willingness to complete the patient-reported outcome questionnaire TASQ, where applicable. Exclusion Criteria: * Participation in any clinical study involving disease modifying therapies for multiple sclerosis during the study period or at the time of enrollment. * Prior treatment with rituximab. * Contraindications to ocrelizumab as per the local prescribing information. * Severe psychiatric or cognitive impairment that, in the opinion of the treating physician, would preclude informed consent, reliable participation in the study, or completion of patient-reported outcomes. * Any condition which, in the opinion of the treating physician, would interfere with participation in the study or the interpretation of study results. * For participants participating in a Market Research and Patient Support Program (MAP), inclusion is permitted only when a cross-reference to the unique MAP patient identifier is available.
Conditions2
Multiple SclerosisRelapsing Remitting Multiple Sclerosis
Interventions1
Related trials
- A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis — Biocad
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) — Hoffmann-La Roche
- A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) — Hoffmann-La Roche
- An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment — Hoffmann-La Roche
- Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Novartis Pharmaceuticals
- Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — Johns Hopkins University
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorHoffmann-La Roche
Started2026-09-23
Est. completion2029-01-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07827586